# V1 Empirics Check — openai/gpt-oss-120b (Variant B)

**Model:** openai/gpt-oss-120b
**Variant:** B
**Date:** 2026-03-25T16:21:37.544634

---

**Referee Report – “The Fiscal Shadow of the Pill Mill: Triplicate Prescriptions, Oxycodone Supply, and Medicaid Treatment Demand”**  

---

### 1. Idea Fidelity  
*No research‑question manifest was supplied, so this section is omitted.*

---

### 2. Summary  
The paper exploits the pre‑1988 adoption of triplicate‑prescription programs in seven states as an instrument for state‑level oxycodone shipments (2006‑2012) in order to estimate the causal effect of opioid supply on later Medicaid medication‑assisted‑treatment (MAT) utilization (2018‑2024). Using DEA ARCOS data and newly released T‑MSIS Medicaid claims, the author finds a point estimate of roughly a one‑for‑one elasticity (≈ 0.8–1.2) but with very large standard errors; a placebo test using non‑opioid substance‑use treatment delivers a null result, supporting the exclusion restriction.

---

### 3. Essential Points  

1. **Instrument Weakness and Limited Variation**  
   * The first‑stage F‑statistic falls to **5.7** once the three controls are added, which is below the conventional rule‑of‑thumb (F > 10) for a strong instrument. With only **seven** treated states, the identification rests on a very thin cross‑section. The resulting IV estimates are imprecise (standard errors ≈ 1) and the confidence interval comfortably includes zero. This raises serious concerns that the reported elasticity is driven by sampling noise rather than a robust causal relationship.  

2. **Potential Violation of the Exclusion Restriction**  
   * Triplicate‑prescription programs were introduced for broad Schedule II monitoring and may have been correlated with other state‑level policies (e.g., early adoption of prescription‑drug‑monitoring programs, differing law‑enforcement intensity, or historic attitudes toward substance‑use treatment). The author’s “30‑year lag” argument is insufficient because the same institutional environment that prompted triplicate adoption could plausibly affect later Medicaid enrollment rules, provider networks, or funding streams that directly influence MAT claims. The single placebo test (non‑opioid SUD) does not rule out all such channels.  

3. **External Validity and Generalizability**  
   * The analysis is restricted to **state‑level aggregates** and to **Medicaid** enrollees only. The ARCOS supply data end in 2012, while the opioid market (especially the rise of illicit fentanyl) changed dramatically thereafter. Consequently, the estimated “supply‑to‑treatment pipeline” may not apply to the current opioid environment or to other insurance populations, limiting the policy relevance of the results.  

If any of these three points cannot be adequately addressed, the manuscript should be **rejected**. Below are concrete suggestions for how the authors might resolve them.

---

### 4. Suggestions  

Below are detailed, constructive recommendations that, if implemented, would substantially strengthen the paper. The bulk of the review focuses on these items because they are essential for establishing a credible causal claim and for making the contribution useful to the broader literature.

#### A. Strengthening the Instrument  

1. **Augment the Identification Strategy**  
   * **Add a second, independent instrument** (e.g., timing of state‑level PDMP implementation, or variation in the proportion of “high‑risk” prescribers before OxyContin launch). A two‑instrument approach would enable over‑identification tests and could raise the first‑stage F‑statistic.  
   * **Exploit within‑state variation** if possible. County‑level ARCOS data are publicly available; constructing a panel at the county level would increase the number of treated observations and allow fixed‑effects controls for time‑invariant county characteristics.  

2. **Report First‑Stage Robustness**  
   * Present the first‑stage results **with and without each control** and **with alternative specifications** (e.g., limiting controls to pre‑2000 variables). Show that the coefficient on the triplicate indicator is stable and that the F‑statistic remains comfortably above 10 in at least one specification.  
   * Include a **weak‑instrument robust inference** approach (e.g., the Anderson‑Rubin test, conditional likelihood ratio, or the LIML estimator) as a primary robustness check, not just a supplemental note.  

3. **Power / Precision Analysis**  
   * Conduct a formal **Monte‑Carlo or analytical power calculation** to demonstrate the attainable precision given the sample size and instrument strength. If the current design simply lacks power, this should be acknowledged and a recommendation for larger‑scale data (e.g., county‑level) made explicit.

#### B. Bolstering the Exclusion Restriction  

1. **Falsification Tests Beyond Non‑Opioid SUD**  
   * Test the instrument against **outcomes that should be unaffected by opioid supply** but could be influenced by broader state policy environments, such as:  
     - Medicaid enrollment rates for unrelated services (e.g., diabetes or preventive care).  
     - Hospital admission rates for non‑substance‑related diagnoses.  
   * Use these tests to demonstrate that the triplicate indicator does **not** predict a broad set of unrelated outcomes, thereby strengthening confidence that the only channel is through oxycodone supply.  

2. **Historical Policy Controls**  
   * Include **pre‑2000 variables** that capture the regulatory environment (e.g., year of PDMP adoption, felony‑related drug‑law enforcement intensity, state‑level opioid prescribing caps). If such variables are correlated with the triplicate indicator, they can be added as controls or used to construct a **difference‑in‑differences‑in‑differences** design that isolates the effect of the triplicate policy itself.  

3. **Mechanism Checks**  
   * Show that **oxy‑codone supply mediates the effect** on MAT by reporting a **mediation analysis** (e.g., a two‑stage residual inclusion approach) that explicitly decomposes the total effect into the portion transmitted through oxycodone shipments versus any residual direct effect of the triplicate indicator.  

#### C. Expanding the Data and External Validity  

1. **Update Supply Measures**  
   * Incorporate **more recent ARCOS data** (up to at least 2016) to capture supply dynamics after the initial OxyContin wave and before the fentanyl surge. This will help determine whether the identified elasticity is stable across different supply eras.  

2. **Broaden Outcome Scope**  
   * Complement Medicaid MAT claims with **TEDS (Treatment Episode Data Set)** or **NHSS (National Health Statistics Survey)** data that include non‑Medicaid populations. Even a descriptive comparison would contextualize the magnitude of the effect for the entire U.S. population.  

3. **Geographic Granularity**  
   * If feasible, construct a **county‑level panel** for both supply and treatment outcomes. This would enable the authors to explore heterogeneity (urban vs. rural, high‑poverty vs. low‑poverty counties) and to include **county fixed effects**, which better control for unobserved confounders that vary across states.  

4. **Long‑Run Dynamics**  
   * The current lag (≈ 10–15 years) is plausible but not explicitly justified. Consider estimating a **distributed lag model** that allows for treatment effects to evolve over time (e.g., 2‑year, 5‑year, 10‑year lags). This would clarify whether the “fiscal shadow” is truly persistent or decays after a certain horizon.  

#### D. Presentation and Transparency  

1. **Full Confidence Intervals**  
   * All tables should report **95 % confidence intervals** (or standard errors) alongside point estimates. Readers need to see the range of plausible values, especially given the large standard errors.  

2. **Clarify Sample Construction**  
   * Provide a **flowchart** that shows how the ARCOS and T‑MSIS datasets were merged, how missing observations were handled, and whether any states were excluded (e.g., due to incomplete NPI geocoding).  

3. **Sensitivity to Outliers**  
   * The leave‑one‑out analysis shows sensitivity to Illinois and Idaho. Include **influence diagnostics** (e.g., Cook’s distance) and discuss why these states differ. If they are outliers, consider reporting results **with and without** them, and explain the substantive reasons for any differences.  

4. **Economic Interpretation**  
   * Translate the elasticity into a **dollar amount** (e.g., a 10 % increase in oxycodone supply translates into an X % increase in Medicaid spending, amounting to $Y million). This will make the policy implication clearer for readers and policymakers.  

5. **Reference Updates**  
   * Verify that all cited pre‑prints (e.g., Alpert, Powell & Pacula 2022) have been formally published, and update citations to the final versions where possible.  

#### E. Minor Technical Corrections  

| Issue | Recommendation |
|-------|----------------|
| Table 1 “Population (millions)” values appear inconsistent (e.g., 16 596 600 for triplicate states). | Double‑check the population figures and correct the typographical error. |
| In Equation (1) the dependent variable is logged, but the coefficient is interpreted as a “percentage” change. | Clarify that the coefficient is a semi‑elasticity (percent change in oxycodone supply for a unit change in the triplicate indicator). |
| The abstract mentions “one‑standard‑deviation increase” but the body reports log‑log coefficients. | Ensure consistency: either present results in standardized units throughout or stick to log‑log elasticities. |
| The place‑holder author line (“@CONTRIBUTOR_GITHUB”) should be replaced with real names for the journal’s record. | Add proper attribution before submission. |

---

### Concluding Assessment  

The paper tackles an important and under‑explored question: the fiscal consequences of early‑2000s opioid‑pharmaceutical distribution decisions for today’s Medicaid treatment system. The use of the historic triplicate‑prescription policy as an instrument is novel and potentially valuable. However, the current identification strategy is fragile—instrument strength is marginal, the exclusion restriction is not convincingly isolated, and the sample size is too small to generate precise estimates. Moreover, the analysis is confined to state‑level Medicaid data, which limits external validity.

If the authors can **substantially reinforce the instrument**, **provide richer falsification evidence**, and **expand both the data and the robustness checks**, the paper would make a meaningful contribution to the literature on opioid supply and public‑payor treatment costs. As it stands, the manuscript requires major revisions before it can be recommended for publication.
